CRVS Corvus Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1626971 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-326.6%
TTM EPS YoY-33.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-45.9%
ROA-42.3%
ROIC (approx.)-40.8%
Asset turnover—
Leverage & solvency
Liabilities / assets6.9%
Debt / equity0.00x
Current ratio13.38x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.73x
Accruals ratio-11.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $17.78M | $15.96M | $11.18M | $9.94M | $8.45M | $7.87M | $7.45M | $5.97M |
| SG&A expense | $3.58M | $3.33M | $3.70M | $2.28M | $2.12M | $2.39M | $2.47M | $2.13M |
| Operating income | -$21.36M | -$19.30M | -$14.88M | -$12.22M | -$10.57M | -$10.26M | -$9.92M | -$8.11M |
| Pretax income | -$19.45M | -$17.25M | -$13.09M | -$11.61M | -$9.83M | -$7.61M | $15.73M | -$9.94M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$20.34M | -$17.96M | -$13.69M | -$12.32M | -$10.16M | -$8.00M | $15.19M | -$12.11M |
| EBITDA | -$21.27M | -$19.26M | -$14.85M | -$12.19M | -$10.54M | -$10.23M | -$9.90M | -$8.09M |
| EPS (basic) | -0.22 | -0.19 | -0.15 | — | -0.12 | -0.10 | 0.21 | — |
| EPS (diluted) | -0.22 | -0.19 | -0.15 | — | -0.12 | -0.10 | -0.13 | — |
| Weighted avg. shares (diluted) | 92.49M | 92.37M | 90.00M | — | 82.84M | 77.77M | 75.15M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $15.01M | $18.91M | $40.10M | $4.58M | $2.87M | $14.69M | $5.00M | $8.74M |
| Short-term investments | $187.93M | $196.32M | $196.61M | $52.17M | — | — | — | $43.22M |
| Receivables | $5,000 | $6,000 | $43,000 | $37,000 | $32,000 | $86,000 | $79,000 | $75,000 |
| Current assets | $206.34M | $220.97M | $239.95M | $58.21M | $66.94M | $75.78M | $45.49M | $54.41M |
| PP&E, net | $801,000 | $830,000 | $282,000 | $220,000 | $221,000 | $249,000 | $165,000 | $151,000 |
| Total assets | $223.88M | $239.27M | $253.19M | $71.12M | $80.47M | $89.46M | $59.44M | $68.91M |
| Current liabilities | $15.42M | $13.67M | $12.11M | $9.38M | $8.07M | $8.51M | $9.28M | $35.40M |
| Total liabilities | $15.56M | $13.95M | $12.52M | $9.91M | $8.71M | $9.23M | $10.11M | $36.34M |
| Shareholders' equity | $208.32M | $225.33M | $240.68M | $61.20M | $71.77M | $80.23M | $49.33M | $32.57M |
| Shares outstanding | 84.32M | 84.12M | 84.09M | 74.70M | 74.68M | 74.51M | 68.17M | 67.90M |
| Cash flow statement | ||||||||
| Operating cash flow | -$12.21M | -$15.40M | -$10.37M | -$9.19M | -$9.57M | -$5.78M | -$8.26M | -$8.46M |
| Capital expenditure | $66,000 | $582,000 | $91,000 | $25,000 | $0 | $113,000 | $36,000 | — |
| Free cash flow | -$12.28M | -$15.98M | -$10.46M | -$9.22M | -$9.57M | -$5.89M | -$8.30M | — |
| Investing cash flow | $7.52M | -$5.96M | -$144.85M | $10.88M | -$2.62M | -$20.30M | $4.24M | -$6.08M |
| Financing cash flow | $805,000 | $166,000 | $190.75M | $20,000 | $360,000 | $35.77M | $279,000 | $18.61M |
| Depreciation & amortization | $95,000 | $34,000 | $29,000 | $26,000 | $28,000 | $29,000 | $22,000 | $20,000 |
| Stock-based compensation | $2.83M | $2.61M | $2.65M | $1.57M | $1.25M | $1.26M | $1.25M | $813,000 |
Free plan shows the latest 8 periods; Pro shows all 47 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.